Huang Qingxia, Li Jing, Chen Jinjin, Zhang Zepeng, Xu Peng, Qi Hongyu, Chen Zhaoqiang, Liu Jiaqi, Lu Jing, Shi Mengqi, Zhang Yibin, Ma Ying, Zhao Daqing, Li Xiangyan
Research Center of Traditional Chinese Medicine, College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, Jilin, China.
Northeast Asia Research Institute of Traditional Chinese Medicine, Key Laboratory of Active Substances and Biological Mechanisms of Ginseng Efficacy, Ministry of Education, Jilin Provincial Key Laboratory of Bio-Macromolecules of Chinese Medicine, Changchun University of Chinese Medicine, Changchun, Jilin, China.
J Ginseng Res. 2023 May;47(3):408-419. doi: 10.1016/j.jgr.2022.10.004. Epub 2022 Oct 20.
Ginsenoside compound K (CK), the main active metabolite in , has shown good safety and bioavailability in clinical trials and exerts neuroprotective effects in cerebral ischemic stroke. However, its potential role in the prevention of cerebral ischemia/reperfusion (I/R) injury remains unclear. Our study aimed to investigate the molecular mechanism of ginsenoside CK against cerebral I/R injury.
We used a combination of and models, including oxygen and glucose deprivation/reperfusion induced PC12 cell model and middle cerebral artery occlusion/reperfusion induced rat model, to mimic I/R injury. Intracellular oxygen consumption and extracellular acidification rate were analyzed by Seahorse multifunctional energy metabolism system; ATP production was detected by luciferase method. The number and size of mitochondria were analyzed by transmission electron microscopy and MitoTracker probe combined with confocal laser microscopy. The potential mechanisms of ginsenoside CK on mitochondrial dynamics and bioenergy were evaluated by RNA interference, pharmacological antagonism combined with co-immunoprecipitation analysis and phenotypic analysis.
Ginsenoside CK pretreatment could attenuate mitochondrial translocation of DRP1, mitophagy, mitochondrial apoptosis, and neuronal bioenergy imbalance against cerebral I/R injury in both and models. Our data also confirmed that ginsenoside CK administration could reduce the binding affinity of Mul1 and Mfn2 to inhibit the ubiquitination and degradation of Mfn2, thereby elevating the protein level of Mfn2 in cerebral I/R injury.
These data provide evidence that ginsenoside CK may be a promising therapeutic agent against cerebral I/R injury via Mul1/Mfn2-mediated mitochondrial dynamics and bioenergy.
人参皂苷Compound K(CK)是[具体物质]中的主要活性代谢产物,在临床试验中显示出良好的安全性和生物利用度,并在脑缺血性卒中中发挥神经保护作用。然而,其在预防脑缺血/再灌注(I/R)损伤中的潜在作用仍不清楚。我们的研究旨在探讨人参皂苷CK抗脑I/R损伤的分子机制。
我们使用了[具体方法1]和[具体方法2]模型的组合,包括氧糖剥夺/再灌注诱导的PC12细胞模型和大脑中动脉闭塞/再灌注诱导的大鼠模型,以模拟I/R损伤。通过海马多功能能量代谢系统分析细胞内氧消耗和细胞外酸化率;通过荧光素酶法检测ATP产生。通过透射电子显微镜和MitoTracker探针结合共聚焦激光显微镜分析线粒体的数量和大小。通过RNA干扰、药理学拮抗结合免疫共沉淀分析和表型分析评估人参皂苷CK对线粒体动力学和生物能量的潜在机制。
人参皂苷CK预处理可减轻DRP1的线粒体易位、线粒体自噬、线粒体凋亡以及在[具体模型1]和[具体模型2]模型中抗脑I/R损伤的神经元生物能量失衡。我们的数据还证实,给予人参皂苷CK可降低Mul1和Mfn2的结合亲和力,以抑制Mfn2的泛素化和降解,从而提高脑I/R损伤中Mfn2的蛋白水平。
这些数据提供了证据,表明人参皂苷CK可能是一种有前景的治疗剂,可通过Mul1/Mfn2介导的线粒体动力学和生物能量来对抗脑I/R损伤。